Cited by 1,635Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Open access

Gibney, Geoffrey T, Weiner, Louis M, Atkins, Michael B·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30406-5PMC PMC5702534

Open this paper in CoChat — free account

Abstract

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30406-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Show all 76 references

Sorted by citations

Items 901–1,000 of 1,002

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
Chen, H., Feng, Y., Zhou, Y. L., Tao, Y., Tang, L. M., & Shi, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03224-2 · Cited by 12
NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
Li, H., Zhang, Q., Duan, Q., Tan, Y., Sun, T., & Qi, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894110 · Cited by 12
External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
Glehr, G., Riquelme, P., Zhou, J. Y., Cordero, L., Schilling, H., Kapinsky, M., Schlitt, H. J., Geissler, E. K., Burkhardt, R., Schmidt, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011040 · Cited by 14
Precision immunotherapy
Obradović, A. (2023) · Science · doi:10.1126/science.adg5585 · Cited by 12
The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
Gao, W., Liu, Q., Zhou, Y., Yang, M., & Yu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231206705 · Cited by 12
The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Han, R. H., Dunn, G. P., Chheda, M. G., & Kim, A. H. (2019) · Oncotarget · doi:10.18632/oncotarget.27328 · Cited by 12
Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer
Liu, Y., Huang, Z., Wei, Y., Zhang, M., Li, X., Yang, S., & Wang, H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02678-6 · Cited by 12
Integrative assessment of clinicopathological parameters and the expression of PD‑L1, PD‑L2 and PD‑1 in tumor cells of retroperitoneal sarcoma
Miyake, M., Oda, Y., Nishimura, N., Morizawa, Y., Ohnishi, S., Hatakeyama, K., Fujii, T., Hori, S., Gotoh, D., Nakai, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12052 · Cited by 12
TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Schiavina, R., Liang Cheng, C., Antonio Lopez-beltran, B., Brunocilla, E., Montironi, R., et al. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1109 · Cited by 12
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity
Lucas, M. W., Burton, E. M., Dimitriadis, P., Huang, A. C. C., Long, G. V., Mitchell, T. C., Amaria, R. N., & Blank, C. U. (2025) · Immunity · doi:10.1016/j.immuni.2025.11.021 · Cited by 15
Field-effect-informed urine liquid biopsy for bladder cancer
Shi, W. T., Liu, K. J., Esfahani, M. S., Mach, K. E., Phillips, N. A., Almanza, D., Bajpai, R. K., Schroers‐Martin, J. G., Trabanino, L., Lee, T. J., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.054 · Cited by 13
An evaluation of talimogene laherparepvec for the treatment of melanoma
Broman, K. K., & Zager, J. S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1689951 · Cited by 11
SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer
Yang, W., Han, B., Chen, Y., & Geng, F. (2022) · Aging · doi:10.18632/aging.204224 · Cited by 13
Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study
Zhang, W., Li, S., Zhang, C., Mu, Z., Chen, K., & Xu, Z. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2228991 · Cited by 11
KLF12 transcriptionally regulates PD‐L1 expression in non‐small cell lung cancer
Pan, X., Zhang, W., Wang, L., Guo, H., Zheng, M., Wu, H., Weng, Q., He, Q., Ding, L., & Yang, B. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13512 · Cited by 13
Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside
Montoya, C., Spieler, B. O., Welford, S. M., Kwon, D., Pra, A. D., Junior, G. L. L., & Mihaylov, I. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225720 · Cited by 11
Circadian lifestyle determinants of immune checkpoint inhibitor efficacy
Hughes, B. R., Shanaz, S., Ismail-Sutton, S., Wreglesworth, N. I., Subbe, C. P., & Innominato, P. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1284089 · Cited by 12
A predictive radiotranscriptomics model based on DCE-MRI for tumor immune landscape and immunotherapy in cholangiocarcinoma
Chen, L., Yin, G., Wang, Z., Liu, Z., Sui, C., Chen, K., Song, T., Xu, W., Qi, L., & Li, X. (2024) · BioScience Trends · doi:10.5582/bst.2024.01121 · Cited by 11
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer
Foldi, J., Blenman, K., Marczyk, M., Gunasekharan, V., Polanska, A., Gee, R. J., Davis, M., Kahn, A. M., Silber, A. L. M., & Pusztai, L. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07426-3 · Cited by 12
Developing a machine learning-based prognosis and immunotherapeutic response signature in colorectal cancer: insights from ferroptosis, fatty acid dynamics, and the tumor microenvironment
Zhu, J., Zhang, J., Lou, Y., Zheng, Y., Zheng, X., Cen, W., Ye, L., & Zhang, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1416443 · Cited by 11
Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS -Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Principe, D. R., Pasquinelli, M. M., Nguyen, R. H.-T., Munshi, H. G., Hulbert, A., Aissa, A. F., & Weinberg, F. D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0153 · Cited by 12
Immune-related adverse events of immune checkpoint inhibitors
Tadano, H., & Torigoe, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.102 · Cited by 11
Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
Cao, R., Ma, J., Zhang, S., Sun, L., Liu, Y., Zhang, X., Jing, W., Huang, L., & Han, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2407 · Cited by 11
Evaluation of immune infiltrating of thyroid cancer based on the intrinsic correlation between pair-wise immune genes
Jia, M., Li, Z., Pan, M., Tao, M., Lu, X., & Yang, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118248 · Cited by 11
Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
Li, M., Kaili, D., & Shi, L. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.19 · Cited by 12
Prediction of Two Molecular Subtypes of Gastric Cancer Based on Immune Signature
Wu, D., Feng, M., Shen, H., Shen, X., Hu, J., Liu, J., Yang, Y., Li, Y., Yang, M., Wang, W., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.793494 · Cited by 11
CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma
Zhou, L. Q., Feng, Y., Li, P., Wang, S., Liu, X., & Xia, S. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s352851 · Cited by 11
Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment
Liang, X., Lin, X., Lin, Z., Lin, W., Peng, Z., & Wei, S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106850 · Cited by 12
PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
Li, X., He, Y., Jiang, Y., Pan, B., Wu, J., Zhao, X., Huang, J., Wang, Q., Cheng, L., & Han, J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.09.003 · Cited by 11
Robust machine−learning based prognostic index using cytotoxic T lymphocyte evasion genes highlights potential therapeutic targets in colorectal cancer
Wang, X., Chan, S., Chen, J., Xu, Y., Dai, L., Han, Q., Wang, Z., Zuo, X., Yang, Y., Zhao, H., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03239-y · Cited by 11
Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back
Elias, R. M., Kapur, P., Pedrosa, I., & Brugarolas, J. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.015 · Cited by 11
A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique
Jayant, K., Sodergren, M. H., Reccia, I., Kusano, T., Zacharoulis, D., Spalding, D. R. C., Pai, M., Jiao, L. R., & Huang, K. (2018) · Cancers · doi:10.3390/cancers10110428 · Cited by 11
Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Payne, K., Pugh, M., Brooks, J., Batis, N., Taylor, G., Nankivell, P., & Mehanna, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218229 · Cited by 11
Management of Non-Colorectal Digestive Cancers with Microsatellite Instability
Zhu, M., Jin, Z., & Hubbard, J. M. (2021) · Cancers · doi:10.3390/cancers13040651 · Cited by 11
Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
Wang, L., Yao, Y., Xu, C., Wang, X., Wu, D., & Hong, Z. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211052154 · Cited by 11
Functions of non-coding RNAs in regulating cancer drug targets
Chai, B., Ma, Z., Wang, X., Xu, L., & Li, Y. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022006 · Cited by 11
Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab
Homšek, A., Radosavljevic, D. Z., Miletić, N., Spasić, J., Jovanović, M., Miljković, B., Stanojković, T., & Vučićević, K. M. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220609125013 · Cited by 11
A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma
Shimizu, T., Fuchimoto, Y., Okita, H., Fukuda, K., Kitagawa, Y., Ueno, S., & Kuroda, T. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.08.023 · Cited by 11
Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
Devaraji, M., & Cheriyan, B. V. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00319-6 · Cited by 16
Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis
Kamat, S., Patel, J., Brown, B. R., & Vyas, A. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2108827 · Cited by 12
Modeling cross‐talk of RNA modification enzymes reveals tumor microenvironment‐associated clinical significance and immunotherapy prediction in hepatobiliary malignancy
Qi, F., Li, J., Qi, Z., Zhou, B., Yang, B., Zhang, J., & Qin, W. (2023) · MedComm · doi:10.1002/mco2.256 · Cited by 10
Mechanistic insights into the interactions between cancer drivers and the tumour immune microenvironment
Mišetić, H., Keddar, M. R., Jeannon, J., & Ciccarelli, F. D. (2023) · Genome Medicine · doi:10.1186/s13073-023-01197-0 · Cited by 10
Machine learning-based natural language processing to extract PD-L1 expression levels from clinical notes
Lin, E. C., Zwolinski, R., Wu, J. T.-Y., La, J., Goryachev, S. D., Huhmann, L., Yildrim, C., Tuck, D. P., Elbers, D. C., Brophy, M. T., et al. (2023) · Health Informatics Journal · doi:10.1177/14604582231198021 · Cited by 11
Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation
Wang, T., Yu, D., Wang, J., Zhu, N., Tang, X.-B., Chen, X., Su, L., & Huang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1250558 · Cited by 10
Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer
Zhang, X., Cai, X., & Yan, C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05499-z · Cited by 12
Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: An updated meta‑analysis and systematic review
Guo, H., Lin, X., Feng, S., Wang, C., Yuan, L., Sheng, X., & Li, D. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2703 · Cited by 10
Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma
Lin, W., Chen, X., Huang, Z., Ding, Q., Yang, H., Li, Y., Lin, D., Lin, J., Zhang, H., Yang, X., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02579-w · Cited by 10
Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer
Chang, C. (2024) · American Journal of Cancer Research · doi:10.62347/aryh6451 · Cited by 10
Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy
Putzu, C., Serra, R., Campus, R., Fadda, G. M., Sini, C., Marongiu, A., Ginesu, G. C., Fois, A. G., Palmieri, G., Zinellu, A., et al. (2024) · Current Oncology · doi:10.3390/curroncol31090367 · Cited by 10
An integrative prognostic and immune analysis of PTPRD in cancer
Ou, C., Peng, Q., & Zeng, C. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022251 · Cited by 9
A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma
Huang, S., Sun, L., Hou, P. K., Liu, K., & Wu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944898 · Cited by 10
Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma
Shen, C.-Y., Chang, W., Chen, Y., Weng, C.-W., Regmi, P., Kier, M. K. K., Su, K., Chang, G., Chen, J., Chen, Y., et al. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00382 · Cited by 10
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
Gabryś, H., Basler, L., Burgermeister, S., Hogan, S., Ahmadsei, M., Pavic, M., Bogowicz, M., Vuong, D., Tanadini-Lang, S., Förster, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.977822 · Cited by 11
Developing an m5C regulator–mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer
Zhang, R., Gan, W., Zong, J., Hou, Y., Zhou, M., Yan, Z., Li, T., Lv, S., Zeng, Z., Wang, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1054700 · Cited by 10
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
Lu, X., Green, B. L., Xie, C., Liu, C., & Chen, X. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100723 · Cited by 10
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Dehghani, T., Shahrjerdi, A., Kahrizi, M. S., Soleimani, E., Ravandeh, S., Merza, M. S., Rahnama, N., Ebrahimzadeh, F., & Bakhshesh, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154470 · Cited by 10
Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
Zheng, G., Lu, Y., Yang, Z., Chen, H., Liang, Q., Zhu, Q., Yan, L., Xiao, X., He, Z., Zhu, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1142862 · Cited by 10
Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy
Mao, X., Cai, Y., Long, S., Pérez‐Losada, J., Mao, J., & Chang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1178568 · Cited by 10
Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei
Lin, Y., Zhu, J., Ma, R., Meng, W., Wang, Z.-Y., Li, X.-B., Ma, R., Wu, H., Xu, H.-B., Gao, Y., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0801 · Cited by 9
Personalizing Oncolytic Immunovirotherapy Approaches
Stergiopoulos, G. M., Iankov, I. D., & Galanis, E. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00689-4 · Cited by 10
High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy
Fujiwara, Y., Kato, S., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M., Conroy, J. M., DePietro, P., Pabla, S., Lippman, S. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109632 · Cited by 11
Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma
Gong, Z., Chen, J., Cheng, J., Sun, C., Jia, Q., Diao, X., & Zhu, B. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.011 · Cited by 10
Cell death in cancer in the era of precision medicine
Raschellà, G., Melino, G., & Gambacurta, A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0048-6 · Cited by 10
Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind, A., & Gisselsson, D. (2021) · Cancer Reports · doi:10.1002/cnr2.1397 · Cited by 9
Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer
Cao, J., Li, J., Yang, X. L., Li, P., Yao, Z., Han, D., Ying, L., Wang, L., & Tian, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4071 · Cited by 10
PD-L1 Expression Associated with Epstein—Barr Virus Status and Patients’ Survival in a Large Cohort of Gastric Cancer Patients in Northern Brazil
Moreira-Nunes, C. A., Martins, C. N. D. S. A. T., Feio, D. C. A., Lima, I. K., Lamarão, L. M., de Souza, C. R. T., Costa, I. B., Maués, J. H. D. S., Soares, P. C., de Assumpção, P. P., et al. (2021) · Cancers · doi:10.3390/cancers13133107 · Cited by 10
The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto, M., Carconi, C., Cerreti, M., Schipilliti, F. M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704942 · Cited by 10
Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade
Maus, R. L. G., Leontovich, A. A., Moore, R. M., Becher, L. R. E., Nevala, W. K., Flotte, T. J., Guo, R. R., Schimke, J. M., Dicke, B. A., Yan, Y., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0146 · Cited by 10
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Ameli, F., Shajareh, E., Mokhtari, M., & Kosari, F. (2022) · BMC Cancer · doi:10.1186/s12885-022-09803-x · Cited by 10
A novel 68Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors
Ge, S., Zhang, B., Li, J., Shi, J., Jia, T., Wang, Y., Chen, Z., Sang, S., & Deng, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106785 · Cited by 10
Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers
Li, Z., Lin, J., Zhang, L., Li, J., Zhang, Y., Zhao, C., & Wang, H. (2020) · Future Oncology · doi:10.2217/fon-2020-0243 · Cited by 10
Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer
Nam, C. H., Koh, J., Ock, C.-Y., Kim, M., Keam, B., Kim, T. M., Jeon, Y. K., Kim, D., Chung, D. H., & Heo, D. S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.178 · Cited by 10
Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer
Gu, X., Chu, L., & Kang, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.894024 · Cited by 10
TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma
Wang, H., Liu, Z., Du, Y., Cheng, X., Gao, S., Gao, Y., & Shang, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210910 · Cited by 9
AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment
Zhang, X., Wang, P., Shi, G., Tang, C. C., & Xue, H. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00266 · Cited by 9
Identification and validation of tryptophan-related gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma reveals a critical role for PTTG1
Wang, Z., Zhang, J., Zuo, C., Chen, H., Wang, L., Xie, Y., Ma, H., Min, S., Wang, X., & Lian, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386427 · Cited by 9
APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis
Fan, Z., Liu, Y., Wang, X., Xu, Y., Huang, R., Shi, W., Qu, Y., Ruan, J., Zhou, C., Zhao, X., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12820-7 · Cited by 9
Osteoimmunology in bone malignancies: a symphony with evil
Song, C., Tong, T., Dai, B., Zhu, Y., Chen, E., Zhang, M., & Zhang, W. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.09.001 · Cited by 10
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives
Jin, X., Zhao, W., Li, G., & Jiang, J. (2025) · Cancer Control · doi:10.1177/10732748251334434 · Cited by 9
Protein and Peptide in Cancer Research: From Biomarker to Biotherapeutics
Seo, J. H., Shin, S., Woo, H. R., An, Y., Youn, A., Kim, S.-Y., Ki, M., & Pack, S. P. (2025) · Cancers · doi:10.3390/cancers17183031 · Cited by 10
Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation
Inoue, H. (2026) · Viruses · doi:10.3390/v18040461 · Cited by 10
The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
Lee, Y. S., Lim, J. H., Ryu, W., Park, M. H., Kim, L., Kim, K., Kim, W. Y., & Nam, H. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-165 · Cited by 9
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma
Li, Y., Shi, X., Mao, B., Wang, L., Wu, L., Li, J., & Jiao, S. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.007 · Cited by 9
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
Keber, C. U., Derigs, M., Schultz, C., Wegner, M., Lingelbach, S., Wischmann, V., Hofmann, R. W., Denkert, C., Hegele, A., & Hänze, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03166-9 · Cited by 9
Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Bartolini, S., & Brandes, A. A. (2022) · Immunotherapy · doi:10.2217/imt-2021-0277 · Cited by 9
Gene-guided OX40L anchoring to tumor cells for synergetic tumor “self-killing” immunotherapy
Lin, L., Hu, Y., Guo, Z., Chen, J., Sun, P., Tian, H., & Chen, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.008 · Cited by 9
Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Kim, J. H., Kim, G. H., Ryu, Y., Kim, S., Kim, H., Yoon, S. K., Cho, Y. M., & Lee, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969569 · Cited by 9
DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer
Yuan, S., Gao, Y., Xia, Y., Wang, Z., & Wang, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1008644 · Cited by 9
A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma
Yang, Y., Wang, X., Liu, R., Gao, L., Chen, J., & Kan, H. (2022) · Journal of Immunology Research · doi:10.1155/2022/4983532 · Cited by 9
Association Between Metastatic Melanoma Response to Checkpoint Inhibitor Therapy and Tumor-Infiltrating Lymphocyte Classification on Primary Cutaneous Melanoma Biopsies
Stephens, M., Aderbigbe, O., Xu, W., Karakousis, G. C., Ming, M. E., & Chu, E. Y. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.4959 · Cited by 10
The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma
Zhou, B., Sha, S., Tao, J., Li, J., Shen, C., Zhu, J., Tan, L., Dong, L., & Huang, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-24879-y · Cited by 9
Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma
Schmidl, B., Vossenkämper, K.-A., Stark, L., Boxberg, M., Stögbauer, F., Feigl, K., Winter, C., Pickhard, A., Wollenberg, B., & Wirth, M. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-022-07775-z · Cited by 9
Behavioral factors to modulate immunotherapy efficacy in cancer
Jongerius, C., Vermeulen, L., van Egmond, M., Evers, A., Buffart, L. M., & Lenos, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1066359 · Cited by 7
Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions
Dinarello, A., Mills, T., Tengesdal, I. W., Powers, N. E., Azam, T., & Dinarello, C. A. (2023) · Cells · doi:10.3390/cells12020294 · Cited by 9
Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy
Nikoo, M., Hassan, Z. F., Mardasi, M., Rostamnezhad, E., Roozbahani, F., Rahimi, S., & Mohammadi, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154473 · Cited by 9
Prediction of pathological complete response in locally advanced head and neck squamous cell carcinoma treated with neoadjuvant chemo-immunotherapy using volumetric multisequence MRI histogram analysis
Liu, H., Zhu, C., Wang, X., Chen, X., Li, Z., & Xian, J. (2024) · Neuroradiology · doi:10.1007/s00234-024-03339-6 · Cited by 9
Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree
Bergerot, P. G., Agarwal, N., Pal, S. K., & Jones, J. O. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2039 · Cited by 9
Discovery and application of immune biomarkers for hematological malignancies
Zafeiris, D., Vadakekolathu, J. N., Wagner, S., Pockley, A. G., Ball, G., & Rutella, S. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1381560 · Cited by 9
Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non–small-cell Lung Cancer
Jiang, T., Liu, H., Qiao, M., Li, X., Zhao, C., Su, C., Ren, S., & Zhou, C. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.018 · Cited by 9
Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas
Ramkissoon, L. A., Britt, N., Guevara, A., Whitt, E., Severson, E. A., Sathyan, P., Gay, L. M., Elvin, J. A., Ross, J. S., Brown, C. A., et al. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0559-4 · Cited by 10

Authors: Gibney, G. T., Weiner, L. M., & Atkins, M. B.
Affiliations: Georgetown University Medical Center (US)
Corresponding author: Gibney, Geoffrey T
ORCID: Gibney, Geoffrey T
Weiner, Louis M
Atkins, Michael B
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-12
Volume: 17
Issue: 12
Pages: e542-e551
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30406-5
PMC: PMC5702534
OpenAlex: W2559382297
Cited by: 1,635
References: 76
Citations by year: 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
FWCI: 11.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA050633, P30CA051008)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
MeSH terms: Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks